Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Citation
Mosenzon O, Wiviott SD, Cahn A, et al. Lancet Diabetes Endocrinol 2019;7:606–17.